The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
The last recurrence in the long-term study occurred at 5.4 years, leading researchers to be more comfortable using the term ...
Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.
The program will help make genetic counselors available to any provider across different medical specialties in Tennessee and ...
Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
In a Phase III trial, divarasib bested first-generation drugs Lumakras and Krazati, which the firm said could make it a new standard of care in KRAS G12C-mutated NSCLC.
Three cases suggest some clinicians lack understanding of relatively common autosomal recessive disorders and are ...
The Phase I/II China-based trial will test the combination in patients with PD-L1-positive, EGFR mutated tumors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results